In vitro activity of U-63196E, a new cephalosporin, against clinical bacterial isolates.

AUTOR(ES)

Eliopoulos, G M

RESUMO

The in vitro activity of U-63196E, a new cephalosporin, was compared with those of other extended-spectrum cephalosporins and penicillins against clinical bacterial isolates. Against Pseudomonas aeruginosa, the activity of U-63196E was comparable to those of cefoperazone and piperacillin, each of which inhibited 90% of strains at concentrations of less than or equal to 16 micrograms/ml. The new drug also demonstrated activity against a variety of other bacterial species, but it was generally less active than cefotaxime, moxalactam, and cefoperazone against members of the family Enterobacteriaceae and staphylococci. The presence of any 1 of 10 plasmid-mediated beta-lactamases in a series of otherwise isogenic laboratory strains of P. aeruginosa resulted in a significant reduction in the activity of U-63196E in comparison with its activity against the parent strain, which lacks these enzymes. Combinations of U-63196E with tobramycin demonstrated bacteriostatic synergism against 11 of 20 clinical isolates of P. aeruginosa.

Documentos Relacionados

• In vitro activity and beta-lactamase stability of U-63196E, a novel cephalosporin.
• In vitro activity of an orally administered cephalosporin, LY164846, against potentially pathogenic respiratory and dermal bacterial isolates.
• In vitro activity of AT-4140 against clinical bacterial isolates.
• Comparative in vitro evaluation of cefpimizole (U-63196E), a new antipseudomonal cephalosporin.
• In Vitro Activity of HR 756, a New Cephalosporin, Against Neisseria gonorrhoeae